Anthrax Working Group

Dale Morse, MD, MS
Advisory Committee on Immunization Practices
June 26, 2008

Working Group Members

- Rob Beck ACIP
- Col Ciselak DoD
- LTC Garman DoD
- Col Hachey DoD
- Jeff Duchin NACCHO
- Dav id Kimbell AAP
- Richard Beigi ACOG
- Nelson Arboleda ISO
- Ed Nuzum NIH
- Julianne Clifford FDA
- Alexandra Worobec FDA
- Christopher Chase AVMA
- Jennifer Wright
- Nancy Messonnier


- Conrad Quinn
- Brian Plikaytis
- Stacey Martin
- Chuck Rose
- Mike McNeil
- Kate Glynn
- Nikki Pesik
- Renee Funk
- Rita Traxler
- John Grabenstein
- Paul Offit

Terms of Reference

Anthrax Vaccine Adsorbed (AVA), Emergent BioSolutions

- 1. Review existing 2000 statement and 2002 supplement
- 2. Review new data on AVA including:
 - a. Safety and immunogenicity data from an interim analysis of CDC's dose reduction and route change study in anticipation of FDA evaluation of Emergent Biosolutions' BLA
 - b. Recently published safety studies
 - c. Publications detailing the 2001 anthrax attacks
 - d. Post exposure prophylaxis with vaccine and antibiotics
 - e. Pre-exposure vaccination
- 3. Revise existing statement and supplement into a single document

Timeline and Activities



Timeline and Activities



Objectives of Today's Anthrax Session

- Provide background information on the use of vaccine pre-event in additional populations
 - Present draft recommendations for the use of AVA in first responder organizations
- Receive feedback from the ACIP on the option recommended by the WG
 - —Vote expected in October